Chunxia Su

5PUBLICATIONS
9CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 07, 2026
Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.

|Jun 12, 2026
Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial.

|Jun 26, 2024
A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations.

Li Wang, Yueran Wu, Zhixuan Ren

|Dec 28, 2021
Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Mengqing Xie, Xin Yu, Xiangling Chu

|Nov 07, 2021
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study.

Xiangling Chu, Huiping Qiang, Mengqing Xie

Pageof 1

Frequent Collaborators

1 joint publications

Juan Zhou

1 joint publications

Li Wang

1 joint publications

Fei Zhou

1 joint publications

Wenhua Liang